Drug intelligence / Profile preview

Shangke Jiegu Pian

Development stage: Unknown
Lead developer: Merro Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Shangke Jiegu Pian is a traditional Chinese medicine (TCM) tablet developed and manufactured by Merro Pharmaceutical. It is composed of twelve ingredients, including Semen Strychni, cinnabar, Carthami flos, Eupolyphaga seu Steleophaga, myrrh, and Notoginseng radix et rhizoma. The formulation is indicated for treating bone fractures, joint injuries, lumbar sprains, and soft tissue trauma. It functions by promoting blood circulation, dispersing blood stasis, reducing swelling, and relieving pain. It is officially recorded in the Chinese Pharmacopoeia and is typically administered orally following fracture reduction to support the healing process.

Brand names: SHANGKEJIEGUPIANShangke Jiegu Pian
Other names: Shangke Jiegupian上客洁骨片

Targets

COX

Beyond the preview

Go deeper on Shangke Jiegu Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shangke Jiegu Pian.

Explore the full profile